Skip to main content Back to Top
Advertisement

7/29/2022

Semaglutide Injection

Products Affected - Description

    • Wegovy 0.25 mg dose subcutaneous solution for injection, Novo Nordisk, 0.25 mg/0.5 mL, pen injector, 4 count, NDC 00169-4525-14
    • Wegovy 0.5 mg dose subcutaneous solution for injection, Novo Nordisk, 0.5 mg/0.5 mL, pen injector, 4 count, NDC 00169-4505-14
    • Wegovy 1 mg dose subcutaneous solution for injection, Novo Nordisk, 1 mg/0.5 mL, pen injector, 4 count, NDC 00169-4501-14

Reason for the Shortage

    • Novo Nordisk did not provide a reason for the shortage.
    • Wegovy is on shortage due to increased demand and issues with contract manufacturers.

Available Products

    • Ozempic 0.25 mg or 0.5 mg doses subcutaneous solution for injection, Novo Nordisk, 2 mg/1.5 mL, pen injector, NDC 00169-4132-12
    • Ozempic 1 mg doses subcutaneous solution for injection, Novo Nordisk, 4 mg/3 mL, pen injector, NDC 00169-4130-13
    • Ozempic 2 mg doses subcutaneous solution for injection, Novo Nordisk, 8 mg/3 mL, pen injector, NDC 00169-4772-12
    • Wegovy 1.7 mg dose subcutaneous solution for injection, Novo Nordisk, 1.7 mg/0.75 mL, pen injector, 4 count, NDC 00169-4517-14
    • Wegovy 2.4 mg dose subcutaneous solution for injection, Novo Nordisk, 2.4 mg/0.75 mL, pen injector, 4 count, NDC 00169-4524-14

Estimated Resupply Dates

    • Novo Nordisk has Ozempic 0.25 mg, 0.5 mg, and 1 mg doses available in limited supply.
    • Novo Nordisk has Wegovy 0.25 mg, 0.5 mg, and 1 mg doses on back order and the company estimates release dates of sometime during the second half of 2022.

Updated

Updated July 29, 2022 by Anthony Trovato, PharmD, BCPS. Created March 14, 2022 by Leslie Jensen, PharmD, Drug Information Specialist. © 2022, Drug Information Service, University of Utah, Salt Lake City, UT.

ADVERTISEMENT

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins


ahfs logo

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.